BBOT
Price
$12.33
Change
+$0.13 (+1.07%)
Updated
Dec 26 closing price
Capitalization
986.26M
60 days until earnings call
Intraday BUY SELL Signals
EVAX
Price
$5.13
Change
+$0.21 (+4.27%)
Updated
Dec 26 closing price
Capitalization
42.79M
Intraday BUY SELL Signals
Interact to see
Advertisement

BBOT vs EVAX

Header iconBBOT vs EVAX Comparison
Open Charts BBOT vs EVAXBanner chart's image
BridgeBio Oncology Therapeutics
Price$12.33
Change+$0.13 (+1.07%)
Volume$95.33K
Capitalization986.26M
Evaxion A/S
Price$5.13
Change+$0.21 (+4.27%)
Volume$78.47K
Capitalization42.79M
BBOT vs EVAX Comparison Chart in %
BBOT
Daily Signal:
Gain/Loss:
EVAX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BBOT vs. EVAX commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBOT is a StrongBuy and EVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (BBOT: $12.33 vs. EVAX: $5.13)
Brand notoriety: BBOT and EVAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBOT: 59% vs. EVAX: 51%
Market capitalization -- BBOT: $986.26M vs. EVAX: $42.79M
BBOT [@Biotechnology] is valued at $986.26M. EVAX’s [@Biotechnology] market capitalization is $42.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBOT’s FA Score shows that 1 FA rating(s) are green whileEVAX’s FA Score has 0 green FA rating(s).

  • BBOT’s FA Score: 1 green, 4 red.
  • EVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, EVAX is a better buy in the long-term than BBOT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBOT’s TA Score shows that 5 TA indicator(s) are bullish while EVAX’s TA Score has 3 bullish TA indicator(s).

  • BBOT’s TA Score: 5 bullish, 3 bearish.
  • EVAX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BBOT is a better buy in the short-term than EVAX.

Price Growth

BBOT (@Biotechnology) experienced а -1.52% price change this week, while EVAX (@Biotechnology) price change was +9.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

BBOT is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBOT($986M) has a higher market cap than EVAX($42.8M). EVAX YTD gains are higher at: 21.363 vs. BBOT (17.429). EVAX has higher annual earnings (EBITDA): -5.06M vs. BBOT (-123.82M). BBOT has more cash in the bank: 468M vs. EVAX (10.6M). BBOT has less debt than EVAX: BBOT (2.89M) vs EVAX (11.3M). EVAX has higher revenues than BBOT: EVAX (7.65M) vs BBOT (0).
BBOTEVAXBBOT / EVAX
Capitalization986M42.8M2,304%
EBITDA-123.82M-5.06M2,447%
Gain YTD17.42921.36382%
P/E RatioN/AN/A-
Revenue07.65M-
Total Cash468M10.6M4,415%
Total Debt2.89M11.3M26%
TECHNICAL ANALYSIS
Technical Analysis
BBOTEVAX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
15%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
15%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
39%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
40%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
47%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
25%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
BBOT
Daily Signal:
Gain/Loss:
EVAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IBNYX25.850.02
+0.08%
Nomura Balanced Fund Class Y
NLSCX18.770.01
+0.05%
Neuberger Berman Long Short C
NQCRX5.71N/A
N/A
Nuveen Large Cap Value Opportunities I
LGOPX25.60-0.08
-0.31%
Lord Abbett Growth Opportunities P
PQIZX14.33-0.17
-1.17%
PIMCO Dividend and Income A

BBOT and

Correlation & Price change

A.I.dvisor tells us that BBOT and VKTX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BBOT and VKTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBOT
1D Price
Change %
BBOT100%
+1.07%
VKTX - BBOT
27%
Poorly correlated
-0.46%
COCP - BBOT
25%
Poorly correlated
-0.16%
PRTC - BBOT
22%
Poorly correlated
-0.21%
VTGN - BBOT
21%
Poorly correlated
+0.07%
EVAX - BBOT
21%
Poorly correlated
+4.27%
More

EVAX and

Correlation & Price change

A.I.dvisor tells us that EVAX and KURA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVAX and KURA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVAX
1D Price
Change %
EVAX100%
+4.27%
KURA - EVAX
31%
Poorly correlated
-3.89%
IRD - EVAX
28%
Poorly correlated
-0.98%
OMER - EVAX
27%
Poorly correlated
+2.28%
SPRB - EVAX
27%
Poorly correlated
+2.07%
REPL - EVAX
26%
Poorly correlated
-1.29%
More